{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:27:36Z","timestamp":1783967256416,"version":"3.55.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Significant genetic variability of metabolism confounds reliable clinical use of methadone because physicians have no way of identifying individual patient metabolism. The methadone\/metabolite ratio (MMR), the numerical ratio of serum methadone to its inactive metabolite ethylidine-dimethyl-diphenypyrrolidine (EDDP), represents the net expression of the genes controlling metabolism. The MMR has been adapted to four established pharmacogenetic metabolic categories: ultra-rapid (URM), extensive (EM, normal), intermediate (IM), and ultra-slow (USM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study reports on the analysis of 1700 paired peak and trough serum samples for methadone and EDDP. The MMR data were stratified by metabolic category. The reliability of these categories and the relationship of the MMR to 2 other laboratory assessments, a peak\/trough ratio (PTR) and a methadone half-life, was tested. Additionally, peak and trough serum levels were analyzed by MMR category.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Each category of MMR identified significantly different mean serum levels (peak and trough), peak\/trough ratios, and half-lives. When serum levels were analyzed, evidence of subtherapeutic serum levels were found, predominantly in the URM and EM categories. Seventeen percent of peak serum levels were greater than 1000 ng (a level indicating potential toxicity) with a range up to 2384 ng, predominantly in the IM and USM categories.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The MMR measures an individual's phenotype for methadone metabolism. The data suggested underdosing in the URM category, as well as evidence of excessive dosing in IM and USM categories. The MMR provides a guide to safe and effective dosing, an alternative to the pharmacokinetically \u2018blind\u2019 dosing algorithms currently in use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/adm.0000000000000620","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T22:38:06Z","timestamp":1581028686000},"page":"431-436","source":"Crossref","is-referenced-by-count":18,"title":["The Use of the Methadone\/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing"],"prefix":"10.1097","volume":"14","author":[{"given":"John J.","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Graas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coburn","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest J.","family":"Vasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fassbender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"R1-20231009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.amjmed.2007.10.009","article-title":"A community-based evaluation of sudden death associated with therapeutic doses of methadone","volume":"121","author":"Chugh","year":"2008","journal-title":"Am J Medicine"},{"key":"R2-20231009","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1001\/jama.1988.03410200081030","article-title":"Implications of methadone maintenance for theories of narcotic addiction","volume":"260","author":"Dole","year":"1988","journal-title":"JAMA"},{"key":"R3-20231009","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0009-9236(99)90090-5","article-title":"Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those that do and do not experience withdrawal and concentration-effects relationships","volume":"65","author":"Dyer","year":"1999","journal-title":"Clin Pharmacol Thera"},{"key":"R4-20231009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment","volume":"61","author":"Eap","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"R5-20231009","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R6-20231009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0019527","article-title":"Contributions of CYP P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response","volume":"6","author":"Fonseca","year":"2011","journal-title":"PLoS One"},{"key":"R7-20231009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cpt1978232175","article-title":"Methadone maintenance: plasma levels and therapeutic outcome","volume":"23","author":"Holmstrand","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20231009","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt1972135part1633","article-title":"Levels of methadone in the plasma in methadone maintenance","volume":"13","author":"Inturrisi","year":"1972","journal-title":"Clin Pharm Thera"},{"key":"R9-20231009","first-page":"13","article-title":"Methadone metabolism in opiate dependent patients","volume":"45","author":"Kapur","year":"2012","journal-title":"J Clinbiochem"},{"key":"R10-20231009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current Concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin Pharmacol Drug Develop"},{"key":"R11-20231009","first-page":"2773","article-title":"Plasma and urine levels of methadone","volume":"73","author":"Kreek","year":"1973","journal-title":"NY State J Med"},{"key":"R12-20231009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000485029","article-title":"Methadone dose adjustments, plasma r-methadone levels and therapeutic outcome of heroin users: a randomized clinical trial","volume":"24","author":"Mannaioni","year":"2018","journal-title":"Eur Addict Res"},{"key":"R13-20231009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/ADM.0000000000000099","article-title":"The effects of methadone dose regimen on neonatal abstinence syndrome","volume":"9","author":"McCarthy","year":"2015","journal-title":"J Addict Med"},{"key":"R14-20231009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/ADM.0000000000000398","article-title":"The use of serum methadone\/metabolite ratios to monitor changing perinatal pharmacokinetics","volume":"12","author":"McCarthy","year":"2018","journal-title":"J Addict Med"},{"key":"R15-20231009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/ADT.0000000000000093","article-title":"Pharmacotherapy in methadone maintenance: clinical utility of peak-trough blood levels","volume":"15","author":"Westermeyer","year":"2016","journal-title":"Addict Disord Their Treatment"},{"key":"R16-20231009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1005910","article-title":"Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients","volume":"12","author":"Yang","year":"2016","journal-title":"PLoS Genetics"},{"key":"R17-20231009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:27:04Z","timestamp":1696879624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000620","relation":{},"ISSN":["1932-0620","1935-3227"],"issn-type":[{"value":"1932-0620","type":"print"},{"value":"1935-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]}}}